1. Home
  2. ESEA vs PGEN Comparison

ESEA vs PGEN Comparison

Compare ESEA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

HOLD

Current Price

$54.15

Market Cap

432.9M

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.43

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESEA
PGEN
Founded
2005
1998
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
432.9M
1.5B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
ESEA
PGEN
Price
$54.15
$4.43
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$62.00
$7.67
AVG Volume (30 Days)
36.2K
4.7M
Earning Date
11-18-2025
11-13-2025
Dividend Yield
5.18%
N/A
EPS Growth
6.77
N/A
EPS
17.38
N/A
Revenue
$223,794,428.00
$6,309,000.00
Revenue This Year
$10.05
$342.78
Revenue Next Year
N/A
$478.46
P/E Ratio
$3.11
N/A
Revenue Growth
7.26
59.20
52 Week Low
$26.30
$0.69
52 Week High
$66.00
$5.23

Technical Indicators

Market Signals
Indicator
ESEA
PGEN
Relative Strength Index (RSI) 36.38 64.73
Support Level $54.90 $3.64
Resistance Level $58.90 $3.75
Average True Range (ATR) 2.53 0.26
MACD -0.75 0.08
Stochastic Oscillator 11.85 91.40

Price Performance

Historical Comparison
ESEA
PGEN

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Share on Social Networks: